FARR, STEPHEN J.,法尔 史蒂芬,法爾 史蒂芬,BOYD, BROOKS,博德 布鲁克斯,博德 布魯克斯
申请号：
TW106128365
公开号：
TW201821071A
申请日:
2017.08.22
申请国别(地区):
TW
年份:
2018
代理人:
摘要：
Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.本案係揭示藥物組合及其等之用途。第一種藥物係與第二種藥物合併。該第一種藥物例如芬氟拉明(fenfluramine)之特徵在於形成包括5-HT2B激動劑，例如具有已知不良副作用之非芬氟拉明的代謝產物。該第二種藥物係以CYP抑制劑之形式例如大麻二酚，其係向下調節代謝產物之形成，從而使第一種藥物更安全。
